Brief Title: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Number of participants with dose limiting toxicities (DLTs)

Primary Outcome 1 - Timeframe: Baseline through day 28

Primary Outcome 2 - Measure: Number of participants with treatment emergent adverse events (AEs)

Primary Outcome 2 - Timeframe: Baseline through up to 2 years or until disease progression

Primary Outcome 3 - Measure: Number of participants with laboratory abnormalities

Primary Outcome 3 - Timeframe: Baseline through up to 2 years or until disease progression

Primary Outcome 4 - Measure: Objective Response Rate

Primary Outcome 4 - Timeframe: Baseline through up to 2 years or until disease progression

CONDITION

• Advanced Solid Tumors
• Metastatic Solid Tumors

ELIGIBILITY

Gender: All

Minimum Age: N/A

Maximum Age: 18 Years

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Pfizer CT.gov Call Center

Role: Study Director

Affiliation: Pfizer

Overall Contact

Name: Pfizer CT.gov Call Center

Phone: 1-800-718-1021

Email: ClinicalTrials.gov_Inquiries@pfizer.com

LOCATION